H-吴越投资2020-03-04 21:57
春节期间对血液灌流治疗进行初步研究,对采用全血灌流和血浆灌流的产品做了一些疏理,附以我个人的一些理解。相关公司列表如下:
表一、血浆吸附:
注:
(1)血浆吸附模式提前将血液中的血细胞分离出来,吸附效率更佳,还可以避免或减少血液相容性问题。血液相容性可能是因为离子树脂...查看全文
$Cytosorbents(CTSO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000834237-21-003789 Act: 34 Size: 13 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-21-003460 Act: 34 Size: 244 KB 网页链接
$Cytosorbents(CTSO)$ 内部交易: 2021-12-31,CFO,BLOCH KATHLEEN P. ,期权,7857普通股, $5.60
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-000337 Size: 9 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001104659-20-134213 Act: 34 Size: 297 KB 网页链接
$Cytosorbents(CTSO)$ 内部交易: 2020-11-10,Director,Kraus Al ,卖出,8000普通股, $8.00
$Cytosorbents(CTSO)$ 内部交易: 2020-11-10,Director,Kraus Al ,期权,8000普通股, $3.45
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-124504 Size: 9 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-20-121457 Act: 34 Size: 418 KB 网页链接
$Cytosorbents(CTSO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001104659-20-121349 Act: 34 Size: 6 MB 网页链接